抗体
腺癌
人源化抗体
噬菌体展示
表位
单克隆抗体
分子生物学
体内
癌症研究
免疫组织化学
化学
细胞外
生物
细胞生物学
癌症
免疫学
遗传学
作者
Michael Babich,James A. Radosevich
标识
DOI:10.1096/fasebj.20.5.lb109-a
摘要
Labyrinthin (Lab) is a human adenocarcinoma (AC) marker recognized by mouse monoclonal antibody MCA44‐3A6 (MCA) and characterized in vitro and in vivo as a membrane associated protein. Computer analyses also signify extracellular epitopes that implicate Lab as a therapeutic adenocarcinoma target. In support, cytotoxin‐conjugated MCA was previously shown to selectively kill adenocarcinoma vs. normal cell co‐cultures. Thus, MCA was sequenced and engineered (Abmaxis, Inc.) to develop humanized anti‐Lab antibody for therapy & diagnostics. VH and VL regions were cloned and a scFv fragment was selected by phage display. Based on computer modeling, an additional library was built to select higher affinity Fabs that were subsequently screened (via Biacore) for binding to Lab. A lead candidate (X509Fab) displayed an affinity (50nM) higher than both the corresponding scFv (380nM) and intact antibody (120nM). Immunohistochemistry confirmed X509Fab bound effectively as MCA to A549 human lung adenocarcinoma cell xenografts; immunoblot analysis verified X509Fab was recognized Lab in A549 cell lyzates, but not to normal WI38 human fibroblasts. The data suggest X509Fab is a diagnostic and therapeutic anti‐adenocarcinoma antibody prototype.
科研通智能强力驱动
Strongly Powered by AbleSci AI